# Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer

> **NCT00041119** · PHASE3 · COMPLETED · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 3871 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** AC regimen
- **DRUG:** cyclophosphamide
- **DRUG:** doxorubicin hydrochloride
- **DRUG:** paclitaxel

## Key facts

- **NCT ID:** NCT00041119
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-05
- **Primary completion:** 2012-04
- **Final completion:** 2014-06
- **Target enrollment:** 3871 (ACTUAL)
- **Last updated:** 2017-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00041119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00041119, "Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00041119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*